Chardan Capital Has Lowered Expectations for Century Therapeutics (NASDAQ:IPSC) Stock Price

Century Therapeutics (NASDAQ:IPSC - Get Free Report) had its target price cut by stock analysts at Chardan Capital from $17.00 to $11.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock.

Other analysts also recently issued reports about the company. Rodman & Renshaw initiated coverage on Century Therapeutics in a research note on Thursday, August 8th. They issued a "buy" rating and a $6.00 price objective for the company. HC Wainwright lowered their price objective on Century Therapeutics from $9.00 to $5.00 and set a "buy" rating for the company in a research note on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $11.60.

Century Therapeutics Trading Up 5.0 %

IPSC stock traded up $0.07 during trading on Thursday, reaching $1.46. 653,856 shares of the stock were exchanged, compared to its average volume of 261,578. The firm's 50 day moving average is $1.52 and its 200 day moving average is $2.24. Century Therapeutics has a twelve month low of $1.14 and a twelve month high of $5.51. The firm has a market cap of $123.69 million, a P/E ratio of -0.79 and a beta of 1.41.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. The firm had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.47 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. During the same period in the prior year, the business posted ($0.55) earnings per share. As a group, analysts predict that Century Therapeutics will post -1.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Century Therapeutics

Institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in shares of Century Therapeutics in the third quarter valued at approximately $27,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Century Therapeutics in the first quarter worth $47,000. Rhumbline Advisers increased its position in Century Therapeutics by 56.0% in the second quarter. Rhumbline Advisers now owns 52,466 shares of the company's stock worth $134,000 after buying an additional 18,828 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Century Therapeutics by 141.7% in the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company's stock worth $192,000 after buying an additional 44,155 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Century Therapeutics by 110.1% in the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company's stock worth $380,000 after buying an additional 78,088 shares during the last quarter. 50.20% of the stock is owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.